This video breaks down the key findings from the SURPASS-3 trial, highlighting how emerging evidence is reshaping expectations for glycaemic control in type 2 diabetes. It explains the role of advanced incretin-based therapy and its impact on HbA1c reduction, time-in-range, and overall metabolic outcomes. We explore why metrics beyond HbA1c are gaining importance in modern diabetes management and how improved glucose stability and broader metabolic benefits may redefine what clinicians consider the new benchmark for treatment success.
Watch the full video now to explore the data and see how these findings could influence your clinical practice. ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties, explicit or implied, about the suitability, reliability, or adequacy of the information,…
